Role of hepcidin and iron metabolism in the onset of prostate cancer

Zhao,Bin; Li,Ruiqian; Cheng,Gang; Li,Zhiyao; Zhang,Zhiping; Li,Jun; Zhang,Guoying; Bi,Chengwei; Hu,Chen; Yang,Libo; Lei,Yonghong; Wang,Qilin

doi:10.3892/ol.2018.8544

June-2018 Volume 15 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2018 Volume 15 Issue 6

Full Size Image

Article

Role of hepcidin and iron metabolism in the onset of prostate cancer

Authors:
- Bin Zhao
- Ruiqian Li
- Gang Cheng
- Zhiyao Li
- Zhiping Zhang
- Jun Li
- Guoying Zhang
- Chengwei Bi
- Chen Hu
- Libo Yang
- Yonghong Lei
- Qilin Wang
View Affiliations / Copyright

Affiliations: Department of Urologic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650118, P.R. China, Department of Orthopedic and Trauma Surgery, Yunnan Second People's Hospital, The Fourth Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650021, P.R. China, Department of Ultrasonic Diagnosis, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650118, P.R. China, Department of Radiology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunan 650118, P.R. China
Pages: 9953-9958
|
Published online on: April 20, 2018

https://doi.org/10.3892/ol.2018.8544
Expand metrics +

Abstract

The present study aimed to understand the roles of hepcidin and iron metabolism in the onset of prostate cancer. The prostate cancer LNCap, PC3 and DU145 cell lines were transfected with small interfering RNA (siRNA) targeting hepcidin to knockdown hepcidin expression in LNCap, PC3 and DU145 cells. The expression levels of hepcidin in prostate cancer and normal prostate RWPE‑1cells were detected by western blot analysis. Exogenous hepcidin was added into the hepcidin‑silenced cell lines. Intracellular iron levels were detected using a fluorescence assay, and the proliferative and migratory capacities of cells were detected using the MTT and wound‑healing assays, respectively. The apoptotic rate was measured using flow cytometry, and changes in the expression of the iron‑export protein ferroportin on the cell membrane were detected by western blot analysis. Hepcidin expression in prostate cancer cells was significantly higher than that of normal prostate cells (P<0.05). Furthermore, the iron levels of hepcidin‑silenced cells (hepcidin‑ve groups) were significantly lower than those in the cells treated with exogenous hepcidin (hepcidin+ve groups) (P<0.05). The proliferative capacity of the hepcidin+ve cells significantly exceeded those of the hepcidin‑ve groups (P<0.05) and increased over time. In the wound‑healing assay, the number of hepcidin+ve cells present within the scratch sites increased compared with hepcidin‑ve cells, indicating a higher migration rate. Additionally, the expression of ferroportin in the hepcidin‑ve groups significantly exceeded that in the hepcidin+ve groups (P<0.05). Hepcidin is involved in the onset of prostate cancer, most likely by reducing ferroportin expression and increasing intracellular iron levels to enhance the proliferation, migration and anti‑apoptotic capacities of cancer cells.

View Figures

View References

1	Ye L, Kynaston HG and Jiang WG: Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). Int J Mol Med. 20:103–111. 2007.PubMed/NCBI
2	Moyer VA: U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 157:120–134. 2012. View Article : Google Scholar : PubMed/NCBI
3	Msaouel P, Pissimissis N, Halapas A and Koutsilieris M: Mechanisms of bone metastasis in prostate cancer: Clinical implications. Best Pract Res Clin Endocrinol Metab. 22:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
4	Torti SV and Torti FM: Iron and cancer: More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar : PubMed/NCBI
5	Johnson M, Autzen P, Robson C, Hoedenmaaker R and Hamdy F: Prognostic value of bone morphogenetic protein 6 expression in clinically organ confined prostate cancer. Eur Urol. 35:5121999.
6	Abbaspour N, Hurrell R and Kelishadi R: Review on iron and its importance for human health. J Res Med Sci. 19:164–174. 2014.PubMed/NCBI
7	Chen D and Xu Y: Relation of iron and cervical cancer. World J Cancer Res. 4:1–3. 2014. View Article : Google Scholar
8	Nemeth E and Ganz T: Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 26:323–342. 2006. View Article : Google Scholar : PubMed/NCBI
9	Legendre C and Garcion E: Iron metabolism: A double-edged sword in the resistance of glioblastoma to therapies. Trends Endocrinol Metab. 26:322–331. 2015. View Article : Google Scholar : PubMed/NCBI
10	Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK and Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 113:1271–1276. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lane DJ, Huang ML and Richardson DR: Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression. Biochem J. 452:e3–e5. 2013. View Article : Google Scholar : PubMed/NCBI
12	Anderson GJ and Frazer DM: Iron metabolism meets signal transduction. Nat Genet. 38:503–504. 2006. View Article : Google Scholar : PubMed/NCBI
13	Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE and Hamdy FC: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer. 78:1219–1223. 1998. View Article : Google Scholar : PubMed/NCBI
14	Malyszko J and Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 30:15–30. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, et al: Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 127:907–919. 2015. View Article : Google Scholar : PubMed/NCBI
16	Citelli M, Bittencourt LL, Da Silva SV, Pierucci AP and Pedrosa C: Vitamin A modulates the expression of genes involved in iron bioavailability. Biol Trace Elem Res. 149:64–70. 2012. View Article : Google Scholar : PubMed/NCBI
17	Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL and Miller JL: Hepcidin, anaemia, and prostate cancer. BJU Int. 107:678–679. 2011. View Article : Google Scholar : PubMed/NCBI
18	Bobinac D, Marić I, Zoricić S, Spanjol J, Dordević G, Mustać E and Fuckar Z: Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J. 46:389–396. 2005.PubMed/NCBI
19	Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A and Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 98:8780–8785. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wrighting DM and Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood. 108:3204–3209. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ganz T and Nemeth E: Hepcidin and disorders of iron metabolism. Annu Rev Med. 62:347–360. 2011. View Article : Google Scholar : PubMed/NCBI
22	De Domenico I, Ward DM and Kaplan J: Hepcidin regulation: Ironing out the details. J Clin Invest. 117:1755–1758. 2007. View Article : Google Scholar : PubMed/NCBI
23	Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, et al: Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 75:2254–2263. 2015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Role of hepcidin and iron metabolism in the onset of prostate cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles